31. The antimetabolite KAT/3BP has in vitro and in vivo anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Civanelli, E.; Arribas, A.J.; Aresu, L.; Risi, G.; Kayali, O.; Stathis, A.; Ko, Y.H.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. (12th June 2019) Authors: Spriano, F.; Tarantelli, C.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; Van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. (12th June 2019) Authors: Spriano, F.; Chung, E.; Napoli, S.; Tarantelli, C.; Gaudio, E.; Cascione, L.; Cavalli, A.; Rinaldi, A.; Kwee, I.; Ye, H.; Rossi, D.; Zucca, E.; Stathis, A.; Jessen, K.; Lannutti, B.; Toretsky, J.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
35. The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models. (December 2016) Authors: Gaudio, E.; Tarantelli, C.; Spriano, F.; Bernasconi, E.; Targa, A.; Dirnhofer, S.; Stathis, A.; Zucca, E.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
36. The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. (December 2016) Authors: Tarantelli, C.; Gaudio, E.; Hillmann, P.; Spriano, F.; Rinaldi, A.; Kwee, I.; Cascione, L.; Fabbro, D.; Stathis, A.; Zucca, E.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
37. THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL). (12th June 2019) Authors: Zelenetz, A.D.; Jagadeesh, D.; Kenkre, V.P.; Reddy, N.M.; Stathis, A.; Salman, H.S.; Asch, A.S.; Soumerai, J.; Jhangiani, H.S.; Iasonos, A.; Patel, K.; Carter, J.; LLorin‐Sangalang, J.; Pagel, J.M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
38. ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24). (17th June 2021) Authors: Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; Li, J.; Zelenetz, A. D. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗